Anti-hPD1-Ni-hIgG4 (S228P)

Monoclonal human IgG4 (S228P) antibody against human PD-1

Anti-hPD1-Ni-hIgG4 (S228P) features the constant region of the human IgG4 (S228P) isotype and the variable region of nivolumab. Nivolumab is a fully human IgG4 (S228P) monoclonal antibody that targets the programmed cell death 1 (PD-1) receptor found on activated T cells, B cells, and myeloid cells. Under normal physiological conditions, PD-1 negatively regulates T cell activation thereby preventing autoimmunity [1]. Under pathological conditions, cancer cells produce PD-L1 (programmed cell death 1 ligand 1), the agonist that binds and activates PD-1. Activated PD-1 enables the cancer cells to evade the immune system. Nivolumab binds and blocks the activation of the PD-1 receptor, thereby resulting in the activation of T cells and cell-mediated immune responses [2, 3]. This antibody contains an engineered hinge region mutation (S228P) designed to prevent exchange of IgG4 molecules. Nivolumab has been approved by the FDA for the treatment of melanoma and metastatic squamous non-small cell lung cancer (NSCLC).
Anti-hPD1-Ni-hIgG4 (S228P) was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.


Specificity: Targets cells expressing human PD-1
Clonality: Monoclonal antibody
Isotype: Human IgG4 (S228P)
Source: CHO cells
Purity: Purified by affinity chromatography with protein G


100 µg purified anti-hPD1-Ni-hIgG4 (S228P) antibody, provided azide-free and lyophilized


- Binding of Anti-hPD1-Ni-hIgG4 (S228P) to human PD-1 has been tested using flow cytometry.
- The complete sequence of this antibody has been verified.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.


1. McDermott D. & Atkins M. 2013. PD-1 as a potential target in cancer therapy. Cancer Med. 2(5): 662–673.
2. Wang C. et al., 2014. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates..Cancer Immunol Res. 2014 Sep;2(9):846-56.
3. Gunturi A. & McDermott DF., 2015. Nivolumab for the treatment of cancer. Expert Opin Investig Drugs. 24(2):253-60.


Anti-hPD1-Ni-hIgG4 (S228P)

Description Human PD-1 (nivolumab) antibody - Human IgG4 (S228P)
Cat. Codehpd1ni-mab114
Unit Size100 µg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "".